-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Tag Archives: IPO
Public Exits and Virtual Biotechs – Dreams or Reality?
Here at the 10th Annual BIO Investor Forum, investors and CEOs are debating “all the options” for private companies. The first panel of the conference explored the backdoor entrance into public markets as chilly winds continue to blow through the latest IPO window. For the lunch plenary, panelists examined the option to go virtual and make capital efficiency a reality. Reverse Mergers It is no secret that the IPO market for biotechs has been tough. Read More >
Reverse Mergers: A Company is Ready to Go Public, or it’s Not
The latest IPO window has stalled. There have been five IPO withdrawals since June and around 30 since 2005. Global macro events are threatening to completely shut it. Reverse mergers have become an increasingly popular option with eight transactions in the last year. Unfortunately, 47 percent of reverse mergers have decreased in value post-close since 2008. At the 2011 BIO Investor Forum, a panel of experts examined the current financing environment and what private executive Read More >
Bioenergy Business Outlook Survey Measures Industry Confidence
Biofuels Digests’ Bioenergy Business Outlook Survey, co-sponsored by BIO, is a quarterly indicator of business confidence, financial outlook and growth intentions. The results of the survey provide valuable insight into the mood of leaders in the bioenergy industry. More than a third of respondents each quarter identify themselves as chief executive or owner of their business. Nearly two-thirds of respondents identify themselves as directly involved in bioenergy production, either as producers, investors, business partners or Read More >
Biotech IPO Window – Still Ajar?
IPO plans for Quark Pharmaceuticals were officially put on hold last week as markets continue to drop and investors shy away from risk. This is the fifth IPO withdrawal since June. Ambit, Agendia and Clarus cited market reasons for their withdrawals, and Advanced BioHealing sought a higher valuation exit via acquisition. Only one biotech IPO, Horizon Pharma, has made it out in the last six months. Of the nine biotech IPOs so far in 2011, Read More >
Biotech IPO Update for May 18th, 2011
There are now eight biotech IPOs for 2011, bringing the total for the recent US IPO window to 28. Post-IPO performance is finally picking up with the median return at +14% for these 28 IPOs. Advanced BioHealing was scheduled to IPO this week, but Shire (SHGPY) came in with a $750M offer to buy the company. Sagent Pharmaceuticals (SGNT) was the most recent IPO, back in April. Sagent is a specialty pharma company selling injectable Read More >
